High-dose versus standard-dose vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): A multicenter, open-label, randomized controlled superiority trial
Randomized Controlled Trial
[키워드] adjusted hazard ratio
Administered
administration
adverse effect
age
anti-infective drugs
baseline
benefit
cancers
conducted
confidence interval
contraindication
coronavirus 2
COVID-19
criteria
death
delirium
diagnosis of COVID-19
diarrhea
died
early administration
eligibility
eligibility criteria
eligible
France
High dose
High-dose
high-dose group
hospital
Hospitalization
ICU
improves
intention-to-treat population
investigator
involved
IQR
less
limitation
Local
median age
medical supervision
Mortality
multicenter
observational studies
Older
older patient
Open-label
open-label design
Organ failure
outcome
overall mortality
oxygen
Oxygen requirement
paO2/fiO2
participant
Patient
Primary outcome
Prognostic factor
protective effect
randomization
Randomized
Randomized controlled trial
Randomly
RCT
respiratory
risk factor
Safety Monitoring Board
SARS-CoV-2
SARS-COV-2 infection
Sex
SpO2
Standard dose
Standard-dose
steering committee
survival
sustained
treat
Treatment
Trial
use of antibiotics
Vitamin D
Vitamin D supplementation
vitamin D supplements
were assessed
with COVID-19
women
worsening
[DOI] 10.1371/journal.pmed.1003999 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1371/journal.pmed.1003999 PMC 바로가기 [Article Type] Randomized Controlled Trial